SQP 22
Alternative Names: SQP-22Latest Information Update: 29 Dec 2025
At a glance
- Originator Shasqi
- Class Antineoplastics; Auristatins; Drug conjugates; Fab fragments
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Oct 2025 Pharmacodynamics and adverse event data from a preclinical trial in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
- 25 Apr 2025 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 31 Oct 2024 Preclinical trials in Solid tumours in USA (Parenteral) prior to October 2024